(Q37401326)

20 August 2017

1 reference

title

New-generation platinum agents for solid tumors (English)

1 reference

20 August 2017

1 reference

Neel Shah

1

1 reference

20 August 2017

Don S Dizon

series ordinal

2

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 February 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

5

1 reference

20 August 2017

issue

1

1 reference

20 August 2017

page(s)

33-42

1 reference

INHIBITION OF CELL DIVISION IN ESCHERICHIA COLI BY ELECTROLYSIS PRODUCTS FROM A PLATINUM ELECTRODE

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

The resurgence of platinum-based cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

Mechanisms of resistance to cisplatin and carboplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

Phase I studies with carboplatin at the Royal Marsden Hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

Oxaliplatin for the treatment of cisplatin-resistant cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

Nephrotoxicity of a novel antineoplastic platinum complex, nedaplatin: a comparative study with cisplatin in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

Phase II study of (glycolate-O,O') diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

Phase I and pharmacokinetic study of an oral platinum complex given daily for 5 days in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

Phase II study of oral platinum drug JM216 as first-line treatment in patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

A phase II trial of JM-216 in cervical cancer: an NCIC CTG study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

Phase II study of oral bis (aceto) ammine dichloro (cyclohexamine) platinum (IV) (JM-216, BMS-182751) given daily x 5 in hormone refractory prostate cancer (HRPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

ZD0473 pharmacokinetics in Japanese patients: a Phase I dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

Results of ZD0473 in platinum-pretreated ovarian cancer: analysis according to platinum free interval.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

A phase II trial of ZD0473 in platinum-pretreated ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

Phase II trial of ZD0473 as second-line therapy in mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

A phase II study of ZD0473 given as a short infusion every 3 weeks to patients with advanced or metastatic breast cancer: a National Cancer Institute of Canada Clinical Trials Group trial, IND 129.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

A phase I study of AMD473 and docetaxel given once every 3 weeks in patients with advanced refractory cancer: a National Cancer Institute of Canada-Clinical Trials Group trial, IND 131.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

Improved synthesis of unique estradiol-linked platinum(II) complexes showing potent cytocidal activity and affinity for the estrogen receptor alpha and beta

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

Platinum(IV) complex with adamantylamine overcomes intrinsic resistance to cisplatin in ovarian cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

Chemical and biological profiles of novel copper(II) complexes containing S-donor ligands for the treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: A phase II multicentric study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.5.1.33

21 January 2018

Identifiers

DOI

10.2217/14796694.5.1.33

1 reference

20 August 2017

1 reference